Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

On track to report topline data from NMRA-511 in Alzheimer’s disease agitation around the end of 2025 Resumed enrollment for KOASTAL-3 and -2 studies in March 2025; anticipate reporting topline major depressive disorder data from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026 Expect to progress M4 positive allosteric modulator (PAM) program into the clinic in mid-2025 Secured $125 million venture debt facility from K2 HealthVentures, with$40 million available in 2025; cash runw ...